Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.
about
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Old and new treatment targets in axial spondyloarthritisNew treatment targets for axial spondyloarthritisSyndesmophyte growth in ankylosing spondylitisLong-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control studyAnkylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitorsBone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis.Multimonth controlled small molecule release from biodegradable thin films.Etoricoxib and the treatment of ankylosing spondylitis.Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.Expression profiling in spondyloarthropathy synovial biopsies highlights changes in expression of inflammatory genes in conjunction with tissue remodelling genes.Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study.Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis.Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression.Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis hip tissues in vitro.Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment.Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.Emerging drugs for axial spondyloarthritis including ankylosing spondylitis.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Management of hip involvement in ankylosing spondylitis.Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications.Advances and challenges in spondyloarthritis imaging for diagnosis and assessment of disease.Epidemiology of spondyloarthritis: a review.Treatment challenges in axial spondylarthritis and future directions.Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Certolizumab pegol in axial spondyloarthritis.Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk.Active axial spondyloarthritis: potential role of certolizumab pegol.Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis.The contribution of imaging in the diagnosis and treatment of axial spondyloarthritis.Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.Referral strategy for early recognition of axial spondyloarthritis: consensus recommendations from the Hong Kong Society of Rheumatology.Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors.Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over tEfficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients.MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis.
P2860
Q24186403-8D69CA49-224B-4698-89E8-6C75EABE31AEQ26777906-1D1D8715-0E68-4260-B32F-DDCA19DD72F2Q28073999-3D3D2521-6EC1-484A-B701-BCD6D501F3D2Q28085617-87CF1812-1028-4876-B255-7E5EB86069FBQ28547208-B847086F-BC23-42BD-A76F-ED06E24FC0A7Q33825162-6949F1EC-0C40-451D-AE63-0996EB3936D2Q34046853-165D63B0-42BB-4167-8963-08FDF02A26FAQ34082780-887ACFFA-916E-4B2E-806A-0056F5970CB0Q34466689-64BE1EE9-AF96-4161-A78D-240869050947Q34808170-7727A42B-30EF-44CA-88FB-E4D81506EB03Q35065306-E58B0B37-7612-48DC-A4DA-A9E1B3380246Q35165774-B085A8CB-A02B-415A-B0F6-5D46851FBA37Q35449032-2302E2AF-A801-4365-BAD9-7F28062EF2E4Q35750515-C558293E-FDE1-436F-B71D-674F7257D9F5Q35854185-812BD676-7EF2-4D2C-97D4-9813D622F181Q36682809-34427699-BEA4-4AA9-A2FB-E7B8A5848040Q37465518-B49A9934-41CA-4BFC-B995-473E0776784EQ37541327-E05E732B-261D-4572-A0AA-09A3CF406DB7Q37612248-D8F4D718-A92C-4B76-BD65-0DD45A3E59D8Q38068578-DD327444-3572-4AA9-A32A-AC23719F6323Q38092899-3D46E257-D41E-4F9C-BF56-5557075E6216Q38102540-8827B369-EBB6-4964-837A-7A8A01FCB98EQ38113682-F458E608-2FEF-4AED-B266-9D780707FB94Q38114838-6CE50FFC-989F-40A7-A0A0-B4DE0575B598Q38124275-16E3C05F-F062-48FB-BA44-054DCECB8E33Q38124281-F8B90E5A-2F1A-4634-A084-2951957ACEC1Q38145501-502543C8-D4DF-487B-8649-779EB48CF602Q38161555-E9F993E1-9F2D-4C88-ADFD-489AC087D04CQ38177340-0F96F9FA-28D2-4C03-8FFE-ABFBBCB90FECQ38194547-9090A136-5A5E-4380-AA2C-5B4C86B21A49Q38240821-3D9E2EE7-9D97-43D7-8500-00B03F773D94Q38265675-208AF803-565A-4685-AB49-9FC6EB0C9954Q38780258-A1AAE37B-5A3D-4ECD-84C2-AA33F146CED1Q38925780-A674559C-5D2C-4D08-8E22-74EE30DCDA16Q39135959-937CC3A4-EFB4-495D-9AAC-9D6D4005ADD0Q39218263-784DF1E1-0C1A-4C12-9405-D642605F8636Q39328132-F94B9963-BF23-4A50-8E36-71267CF0B0CAQ40164708-5509F2CA-2604-48CC-A30F-D6100D7E1443Q40204477-F9784074-4685-4106-AFB8-79AA350AB163Q40436845-515F4047-027D-4648-8E97-11135E185800
P2860
Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@ast
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@en
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@nl
type
label
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@ast
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@en
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@nl
prefLabel
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@ast
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@en
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@nl
P50
P1476
Continuous NSAID use reverts t ...... s with ankylosing spondylitis.
@en
P304
P356
10.1136/ANNRHEUMDIS-2012-201370
P407
P577
2012-04-24T00:00:00Z